CLASS ACTION UPDATE for BMBL, ELMS and FENC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / February 21, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BMBL Shareholders Click Here: https://www.zlk.com/pslra-1/bumble-inc-loss-submission-form?prid=23889&wire=1
ELMS Shareholders Click Here: https://www.zlk.com/pslra-1/electric-last-mile-solutions-inc-f-k-a-forum-merger-iii-corp-loss-submission-form?prid=23889&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23889&wire=1

* ADDITIONAL INFORMATION BELOW *

Bumble Inc. (NASDAQ:BMBL)

This lawsuit is on behalf of all purchasers of the Class A common stock of Bumble directly in Bumble’s secondary public stock offering which took place on or about September 10, 2021.
Lead Plaintiff Deadline: March 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bumble-inc-loss-submission-form?prid=23889&wire=1

According to the filed complaint, (a) Bumble’s paying user growth trends had abruptly reversed in 3Q21 and the Company had actually lost tens of thousands of paying users during the quarter; (b) paying users had been more reluctant to sign up for the Bumble app during 3Q21 because of the recent price hike for paid services on the app; (c) a material number of paying users were leaving the Badoo app, a dating-focused social network, and/or could not make payments through the Badoo app due, in substantial part, to problems arising from the Company’s transition of its payment platform; and (d) as a result of the foregoing, Bumble’s business metrics and financial prospects were not as strong as the Registration Statement had represented.

Electric Last Mile Solutions, Inc. f/k/a Forum Merger III Corp. (NASDAQ:ELMS)

ELMS Lawsuit on behalf of: investors who purchased March 31, 2021 – February 1, 2022
Lead Plaintiff Deadline: April 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/electric-last-mile-solutions-inc-f-k-a-forum-merger-iii-corp-loss-submission-form?prid=23889&wire=1

According to the filed complaint, during the class period, Electric Last Mile Solutions, Inc. f/k/a Forum Merger III Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) ELMS’s previously issued financial statements were false and unreliable; (2) ELMS’s earlier reported financial statements would need restatement; (3) certain ELMS executives and/or directors purchased equity in the Company at substantial discounts to market value without obtaining an independent valuation; (4) on November 25, 2021 (Thanksgiving), the Company’s Board formed an independent Special Committee to conduct an inquiry into certain sales of equity securities made by and to individuals associated with the Company; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

FENC Lawsuit on behalf of: investors who purchased May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23889&wire=1

According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE : Levi & Korsinsky, LLP

View source version on accesswire.com:
https://www.accesswire.com/689630/CLASS-ACTION-UPDATE-for-BMBL-ELMS-and-FENC-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders